• Cedazuridine and decitabine, administered orally as a fixed-dose combination (ASTX727), met the primary endpoint of decitabine exposure equivalence of total 5-day dosing between oral ASTX727 and IV decitabine in the phase 3 ASCERTAIN study in MDS and CMML patients
• The study confirmed that the safety profile and clinical activity of the cedazuridine and decitabine fixed-dose combination was similar to that observed in the phase 1/2 study and similar to the expected clinical profile of decitabine IV
• Astex plans to file a New Drug Application (NDA) with the US FDA by the end of 2019
•…
Instinctif Partners’ Corporate and Capital Markets practice has made two Managing Partner promotions in its UK business.
Nick Woods, who leads the Financial Services team, has become the company’s youngest ever Managing Partner, while Melanie Toyne-Sewell has been promoted within the firm’s Life Sciences team.
Melanie has been with the firm for nine years and leads on capital markets communications within the Life Sciences team. A seasoned financial PR, as well as a qualified accountant, she has developed a strong reputation and network within the European healthcare & life sciences…
Cambridge, 3 June 2019: PIR is delighted to announce the appointment of highly regarded executives to support its planned international expansion.
From today, PIR life sciences executive search and interim management will be joined by Tom Bradley and Stuart Penney as Senior Partners, Gemma Adamante as Senior Executive Researcher and George Owen as Executive Researcher.
These valuable additions to an already strong team will fuel the PIR drive to expand internationally within the life sciences sector.
Tom spent over ten years at Pfizer before…
Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications has closed a further round of investment. The £550k funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018. Joining the original investors is biotech entrepreneur and founder member of the Cambridge Angels, Dr Andy Richards CBE.
Stem cells are revolutionising medicine by enabling new approaches for disease modelling, precision medicine and development of new therapeutics.…
Agility Health Tech is delighted to announce they are now managing the communications on behalf of Stevenage Bioscience Catalyst, marking an exciting development in the business relationship between the two organisations.
About Agility Health Tech
With over 25 years’ experience, Agility Health Tech is a full service consulting and communications agency specialising in the healthcare and life science sectors. From product development to business strategy and marcomms, Agility Health Tech can help advance your products and raise your profile.
AMSBIO reports on a recent published paper** by the Howard Hughes Medical Institute at the Massachusetts Institute of Technology (MIT) investigating why epithelial cells grown in monolayers on a plastic dish are worse at segregating their chromosomes than epithelial cells in vivo or in 3D organoid cultures.This discovery by the MIT researchers could have big implications for scientists growing human tissues in the lab and may also help explain why chromosome mistakes run rampant in cancerous cells – an unanswered question in cancer biology. More broadly, the new…
We are happy to announce the below adversting offer from New Scientist for our members.
Individual Advertising
Standard Branded Advert - £299 (reduced from £599)• Advert branded with logo live for up to 28 days
Enhanced Advert - £450 (reduced from £999)• Same as standard branded advert• Promoted across the website and the homepage• Promoted in our fortnightly newsletter to over 25,000 registered candidates
Targeted Advert - £999 (reduced from £1,599)• Same as an enhanced advert• Advert emailed out to up to 1,000 matching registered candidates
For those clients who have regular…
30 May 2019 - Cambridge UK:
Both One Nucleus and SLAS share a desire to facilitate greater knowledge-sharing, collaboration, connectivity and technology advancement among their respective memberships. The content of One Nucleus and SLAS training courses and events is felt to be very complementary rather than competitive and hence both are keen to collaborate to raise awareness of and engagement in the other’s activities within their own membership groups.
“SLAS is pleased to collaborate with the UK’s One Nucleus to promote and incentivise our members’ participation in what are…
Demonstrating continuing support for immuno-oncology researchers, BioIVT extends excellence in research to help researchers screen novel therapeutics
Westbury, NY – May 29, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will now offer Promega Immune Checkpoint and antibody-dependent cell-mediated cytotoxicity (ADCC) Reporter Bioassays to support immunology and immuno-oncology research. This offering complements BioIVT’s custom assay development services using client-provided cells and reagents.
“BioIVT is…